Sun Pharmaceutical Industries Ltd. closed 9.91% short of its 52-week high of 1,960.20 rupees, which the company reached on ...

Shares of Sun Pharmaceutical Industries Ltd. 524715 inched up 0.08% to 1,785.30 Indian rupees Monday, on what proved to be an ...

Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...

The share price of Sun Pharmaceuticals Industries (Sun Pharma) is shining bright, the top gainer in intra-day trade, up 3%. This surge in the share price came after the company announced an ...

Sun Pharma will pay an upfront cash consideration of $4.1 per share, representing a 66 percent premium to Checkpoint’s last closing price. Additionally, Checkpoint shareholders will receive a ...

India's pharma giant Sun Pharma is to acquire Checkpoint Therapeutics (NASDAQ:CKPT)—an immunotherapy and targeted oncology company—for an upfront cash payment o ...

Upon completion of the transaction, Sun Pharma will acquire all outstanding shares of Checkpoint and Checkpoint stockholders will receive, for each share of common stock they hold, an upfront cash ...

India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics , a U.S.-based immunotherapy and targeted oncology company, for $355 million.

Under the deal, Sun Pharma will acquire all outstanding shares of Checkpoint and Checkpoint stockholders will receive $4.10 per each share of common stock as upfront cash payment and a non ...

to Sun Pharma's global franchise. The deal will be made through an upfront cash payment of $4.10 per common share, a premium of about 66% to Checkpoint's last close on Friday, the Indian pharma ...

Sun Pharma has agreed to purchase the Massachusetts biotech for an upfront value of $355 million, or $4.10 per share, the companies said Sunday. With Unloxcyt, an FDA-approved PD-L1 therapy for ...